Richard Pops - Acceleron Pharma Independent Director
Director
Mr. Richard F. Pops is an Independent Director of the Company. He has served as a member of our Board of Directors since 2004. Since 2011, Mr. Pops has served as Chief Executive Officer and Chairman of the board of Alkermes plc, the parent company of Alkermes. From 2009 to 2011, Mr. Pops served as Chief Executive Officer and Chairman of the Board of Alkermes, from 2007 to 2009 he served as the Chairman of the board of Alkermes, and from 1991 through 2007 he served as the Chief Executive Officer of Alkermes. Mr. Pops also serves on the board of directors of two other public companies, Neurocrine Biosciences, Inc. and Epizyme Inc., on the board of directors for the Biotechnology Industry Organization and Pharmaceutical Researcher and Manufacturers of America, and the National Health Council. He has previously served on the board of directors of Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Inc. from 2001 to 2009. Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He was a member of the Harvard Medical School Board of Fellows from 2002 through June 2012 since 2004.
| Age | 55 |
| Tenure | 20 years |
| Phone | 617 649-9200 |
| Web | www.acceleronpharma.com |
Richard Pops Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Pops against Acceleron Pharma stock is an integral part of due diligence when investing in Acceleron Pharma. Richard Pops insider activity provides valuable insight into whether Acceleron Pharma is net buyers or sellers over its current business cycle. Note, Acceleron Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Acceleron Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Pops 3 days ago Acquisition by Richard Pops of 1700 shares of Neurocrine Biosciences at 42.76 subject to Rule 16b-3 | ||
Richard Pops over two months ago Acquisition by Richard Pops of 274328 shares of Alkermes Plc at 30.04 subject to Rule 16b-3 |
Acceleron Pharma Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.16) %, meaning that it created substantial loss on money invested by shareholders. Acceleron Pharma's management efficiency ratios could be used to measure how well Acceleron Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.43 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Acceleron Pharma has a current ratio of 14.51, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Acceleron Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Acceleron Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acceleron Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acceleron to invest in growth at high rates of return. When we think about Acceleron Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Olivet | Cedar Fair LP | 57 | |
| Ann Millner | Merit Medical Systems | 65 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
| John Heinmiller | Teleflex Incorporated | 66 | |
| Adrian Reynolds | Academy Sports OutdoorsInc | N/A | |
| Eric Affeldt | Cedar Fair LP | 58 | |
| Claire Milne | Playtech plc | N/A | |
| JeanGuy Martin | Academy Sports OutdoorsInc | N/A | |
| F Millner | Merit Medical Systems | N/A | |
| Candace Duncan | Teleflex Incorporated | 67 | |
| Daniel Hanrahan | Cedar Fair LP | 62 | |
| Nolan Karras | Merit Medical Systems | 72 | |
| John Krumins | Playtech plc | N/A | |
| John Maeda | Sonos Inc | 51 | |
| John Scott | Cedar Fair LP | 53 | |
| Thomas Conrad | Sonos Inc | 48 | |
| Richard Edelman | Merit Medical Systems | 73 | |
| Jill Anderson | Merit Medical Systems | 58 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| Andrew Rubin | JD Sports Fashion | 52 | |
| Anna Massion | Playtech plc | 39 | |
Management Performance
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 |
Acceleron Pharma Leadership Team
Elected by the shareholders, the Acceleron Pharma's board of directors comprises two types of representatives: Acceleron Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acceleron. The board's role is to monitor Acceleron Pharma's management team and ensure that shareholders' interests are well served. Acceleron Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acceleron Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Independent Director | ||
| Terrance McGuire, Independent Director | ||
| Matthew Sherman, Senior Vice President Chief Medical Officer | ||
| Robert Zeldin, Chief Medical Officer | ||
| Christopher Rovaldi, Senior Vice President Program Management and Operations | ||
| Richard Pops, Independent Director | ||
| Ravindra Kumar, Chief Scientific Officer, Vice President | ||
| Thomas McCourt, Director | ||
| Francois Nader, Director | ||
| John Quisel, Vice President General Counsel, Secretary | ||
| Tom Maniatis, Independent Director | ||
| John Knopf, Founder, CEO and President and Director | ||
| Steven Ertel, COO and Executive VP | ||
| George Golumbeski, Independent Director | ||
| Terrence Kearney, Director | ||
| Karen Smith, Director | ||
| Todd James, IR Contact Officer | ||
| Sujay Kango, Chief Commercial Officer | ||
| Kevin McLaughlin, CFO, Sr. VP and Treasurer | ||
| Joseph Zakrzewski, Independent Director | ||
| Habib Dable, President CEO, Director |
Acceleron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acceleron Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 | |||
| Profit Margin | (158.11) % | |||
| Operating Margin | (158.79) % | |||
| Current Valuation | 6.93 B | |||
| Shares Outstanding | 60.7 M | |||
| Shares Owned By Insiders | 11.86 % | |||
| Shares Owned By Institutions | 90.60 % | |||
| Number Of Shares Shorted | 2.12 M | |||
| Price To Earning | (14.74) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Acceleron Stock
If you are still planning to invest in Acceleron Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acceleron Pharma's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |